Anticholinergic and sedative medication use in older patients with cognitive concerns
- PMID: 38685717
- DOI: 10.1111/jgs.18933
Anticholinergic and sedative medication use in older patients with cognitive concerns
Abstract
Background: Anticholinergic (AC) and sedative medications are a risk factor for cognitive impairment. This study sought to characterize AC and sedative use in older patients seen for outpatient neuropsychological evaluation and evaluate their associations with different cognitive domains. We hypothesized that AC and sedative use would be associated with worse attention/processing speed (AP), executive functioning (EF), and memory.
Methods: We conducted a cross-sectional chart review of 392 patients (mean [M] age = 72 ± 7.7 years, range = 54-91). Medications were characterized by number of AC medications (≥1 on the Anticholinergic Cognitive Burden Scale [ACB]), number of sedative medications, and polypharmacy (≥5 daily medications). Demographically adjusted composites were calculated for AP, EF, and memory. Bivariate Pearson correlations assessed relationships between medication use and cognition. Multivariate linear regressions evaluated significant medication-cognition associations, controlling for total medications, medical comorbidities, and estimated premorbid cognitive functioning.
Results: Polypharmacy was common (80%; n = 314). Most patients (70%; n = 275) used ≥1 sedative medications (range = 0-9). Over half (63%; n = 248) used ≥1 AC drugs (range = 0-7), yet ACB scores were ≤2 in 74% of patients. Sedative use was negatively correlated with AP (r = -0.134, p = 0.008) and EF (r = -0.105, p = 0.04). ACB scores were negatively correlated with AP (r = -0.106, p = 0.037). Sedatives and a priori covariates significantly predicted AP performance (R2 = 0.127, p < 0.001); using more sedative medications was uniquely associated with worse AP (β = -0.426, p = 0.049). No significant associations were found with memory.
Conclusion: AC and sedative medications and polypharmacy were prevalent in this sample of older patients. Though both drug classes had negative relationships with AP and EF, sedatives had a particularly negative association with AP. Contrary to our hypotheses, memory was not associated with medication use; however, anticholinergic burden was low within the sample, and AP and EF deficits may masquerade as memory problems.
Keywords: MCI; cognition; dementia; medication use.
© 2024 The American Geriatrics Society.
Similar articles
-
Anticholinergic/sedative drug burden predicts worse memory acquisition in older racially/ethnically diverse patients with type 2 diabetes mellitus.Int J Geriatr Psychiatry. 2019 Oct;34(10):1545-1554. doi: 10.1002/gps.5173. Epub 2019 Jul 22. Int J Geriatr Psychiatry. 2019. PMID: 31313847 Free PMC article.
-
Anticholinergic and sedative medications exposure in older patients: a cross-sectional study.Int J Clin Pharm. 2019 Oct;41(5):1152-1158. doi: 10.1007/s11096-019-00885-5. Epub 2019 Aug 7. Int J Clin Pharm. 2019. PMID: 31392583
-
Anticholinergic Burden and Cognition in Older Patients With Schizophrenia.J Clin Psychiatry. 2017 Nov/Dec;78(9):e1284-e1290. doi: 10.4088/JCP.17m11523. J Clin Psychiatry. 2017. PMID: 29188908
-
Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models.Drugs Aging. 2021 Nov;38(11):977-994. doi: 10.1007/s40266-021-00895-x. Epub 2021 Nov 9. Drugs Aging. 2021. PMID: 34751922 Free PMC article.
-
Drug Burden Index in older adults: theoretical and practical issues.Clin Interv Aging. 2014 Sep 9;9:1503-15. doi: 10.2147/CIA.S66660. eCollection 2014. Clin Interv Aging. 2014. PMID: 25246778 Free PMC article. Review.
Cited by
-
An Unusual Presentation of Respiratory Dysfunction in Parkinson's Disease: A Case Study.Cureus. 2025 Jan 7;17(1):e77101. doi: 10.7759/cureus.77101. eCollection 2025 Jan. Cureus. 2025. PMID: 39917160 Free PMC article.
-
Anticholinergic and sedative medication use in persons with HIV: defining the evidence for risks on cognition.AIDS. 2024 Nov 1;38(13):1885-1887. doi: 10.1097/QAD.0000000000003994. Epub 2024 Sep 26. AIDS. 2024. PMID: 39325004 No abstract available.
References
REFERENCES
-
- Shmuel S, Pate V, Pepin MJ, et al. Quantifying cumulative anticholinergic and sedative drug load among US Medicare beneficiaries. Pharmacoepidemiol Drug Saf. 2021;30(2):144‐156. doi:10.1002/pds.5144
-
- Casagrande M, Marselli G, Agostini F, Forte G, Favieri F, Guarino A. The complex burden of determining prevalence rates of mild cognitive impairment: a systematic review. Front Psych. 2022. Accessed October 19, 2023;13:960648. doi:10.3389/fpsyt.2022.960648
-
- Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1–2):125‐132. doi:10.1159/000109998
-
- Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long‐term benzodiazepine use: a meta‐analysis. CNS Drugs. 2004;18(1):37‐48. doi:10.2165/00023210‐200418010‐00004
-
- Boustani M, Campbell N, Munger S, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311‐320. doi:10.2217/1745509X.4.3.311
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical